

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) An electrotransport device, comprising:
~~a first and second electrodes~~ electrode;
a first reservoir adapted to receive an active agent formulation;
~~a second reservoir adapted to receive an electrolyte formulation,~~
said first reservoir being in communication with said electrode,
~~said second reservoir being in communication with said second electrode;~~
a power source;
electronic circuitry in communication with ~~at least said first and second electrodes~~
electrode;
a non-conductive reservoir housing having an internal cavity containing said first electrode and said first reservoir, said reservoir housing including an electrically conductive element integrally molded within the non-conductive housing and having a first end in communication with said first reservoir and a second end that is disposed on the outside of said reservoir housing and extends therefrom, said second end of said conductive element being adapted to be operatively connected to said power source, whereby electrical communication between said first reservoir, said electronic circuitry and said power source is provided.
2. (Original) The electrotransport device of Claim 1, wherein said power source is in communication with said electronic circuitry and said second end of said conductive element is adapted to be connected to said electronic circuitry.
3. (Original) The electrotransport device of Claim 1, wherein said conductive element comprises a substantially planar member.
4. (Original) The electrotransport device of Claim 2, wherein said conductive element is substantially flexible.

5. (Original) The electrotransport device of Claim 1, wherein said conductive element includes a base member having a conductive coating disposed thereon.

6. (Previously Presented) The electrotransport device of Claim 1, wherein said active agent formulation includes a therapeutic agent selected from the group consisting of anti-infectives; analgesics; anesthetics; anorexics; antiarthritics; antiasthmatic agents; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihistamines; anti-inflammatory agents; antimigraine preparations; antmotion sickness preparations; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; anticholinergics; sympathomimetics; xanthine derivatives; cardiovascular preparations; beta blockers; beta-agonists; antiarrhythmics; antihypertensives; ACE inhibitors; diuretics; vasodilators; central nervous system stimulants; cough and cold preparations; decongestants; diagnostics; hormones; hypnotics; immunosuppressants; muscle relaxants; parasympatholytics; parasympathomimetics; prostaglandins; proteins; peptides; psychostimulants; sedatives; and tranquilizers.

7. (Previously Presented) The electrotransport device of Claim 6, wherein the anti-infective is an antibiotic or antiviral agent.

8. (Previously Presented) The electrotransport device of Claim 6, wherein the analgesic is fentanyl, sufentanil, remifentanil, buprenorphine or an analgesic combination.

9. (Previously Presented) The electrotransport device of Claim 6, wherein the antmotion sickness preparation is scopolamine or ondansetron.

10. (Previously Presented) The electrotransport device of Claim 6, wherein the antispasmodic is a gastrointestinal or urinary antispasmodic.

11. (Previously Presented) The electrotransport device of Claim 6, wherein the cardiovascular preparation is a calcium channel blocker.

DOCKET NO.: ALZA-0377 (ALZ5016USANP)
Application No.: 10/814,705
Office Action Dated: July 21, 2006

**PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116**

12. (Previously Presented) The electrotransport device of Claim 6, wherein the beta-agonist is dobutamine or ritodrine.
13. (Previously Presented) The electrotransport device of Claim 6, wherein the antihypertensive is atenolol.
14. (Previously Presented) The electrotransport device of Claim 6, wherein the ACE inhibitor is ranitidine.
15. (Previously Presented) The electrotransport device of Claim 6, wherein the vasodilator is a general, coronary, peripheral, or cerebral vasodilator.
16. (Previously Presented) The electrotransport device of Claim 6, wherein the hormone is parathyroid hormone.